3 results
DEFA14A
EX-2.1
FWBI
First Wave BioPharma Inc
14 Mar 24
Additional proxy soliciting materials
6:10am
8-K
EX-2.1
FWBI
First Wave BioPharma Inc
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-2.1
FWBI
First Wave BioPharma Inc
13 Sep 21
Entry into a Material Definitive Agreement
6:17am
- Prev
- 1
- Next